CR 666

Drug Profile

CR 666

Alternative Names: CR666; FE 200666

Latest Information Update: 12 Feb 2015

Price : $50

At a glance

  • Originator Ferring Pharmaceuticals; Freie Universitat Berlin
  • Developer ALZA Corporation
  • Class Analgesics
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 10 Feb 2015 Cara Therapeutics has patent protection for κ opioid receptor agonists in USA
  • 05 Jan 2006 CR 666 licensed to Cara Therapeutics worldwide
  • 30 May 2002 Discontinued - Preclinical for Pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top